Initiator Pharma To Fully Prioritize Pudafensine

About this update from Initiator Pharma A/s

Initiator Pharma A/S OMXSTO:INIT:INITIATOR PHARMA TO FULLY PRIORITIZE PUDAFENSINETO FOCUS FULLY ON ITS MOST PROMISING DRUG CANDIDATE, PUDAFENSINEWILL DISCONTINUE FURTHER DEVELOPMENT OF IP2018RESOURCES FROM IP2018 TO BE REDIRECTED TO PUDAFENSINE DEVELOPMENTPUDAFENSINE PHASE IIA STUDY IN VULVODYNIA EXPECTED TO COMPLETE BY END 2026ADDITIONAL PROOF-OF-CONCEPT DATA IN VULVODYNIA EXPECTED BEFORE YEAR-END

View stock analysis, news, and events for Initiator Pharma A/s